These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 17526542

  • 1. No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy--report from the ItalKid Project database.
    Ardissino G, Viganò S, Testa S, Daccò V, Paglialonga F, Leoni A, Belingheri M, Avolio L, Ciofani A, Claris-Appiani A, Cusi D, Edefonti A, Ammenti A, Cecconi M, Fede C, Ghio L, La Manna A, Maringhini S, Papalia T, Pela I, Pisanello L, Ratsch IM, ItalKid Project.
    Nephrol Dial Transplant; 2007 Sep; 22(9):2525-30. PubMed ID: 17526542
    [Abstract] [Full Text] [Related]

  • 2. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
    Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R, Gaspari F, Remuzzi G.
    Kidney Int Suppl; 1997 Dec; 63():S54-7. PubMed ID: 9407422
    [Abstract] [Full Text] [Related]

  • 3. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.
    Jafar TH, Schmid CH, Stark PC, Toto R, Remuzzi G, Ruggenenti P, Marcantoni C, Becker G, Shahinfar S, De Jong PE, De Zeeuw D, Kamper AL, Strangaard S, Levey AS.
    Nephrol Dial Transplant; 2003 Oct; 18(10):2047-53. PubMed ID: 13679479
    [Abstract] [Full Text] [Related]

  • 4. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C, Rizza V, Paparella M, Casellato D, Napodano P, Olivieri G, D'Amico G.
    J Nephrol; 2009 Oct; 22(3):387-96. PubMed ID: 19557716
    [Abstract] [Full Text] [Related]

  • 5. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S, Sar F, Bengi-Bozkurt O, Kazancioglu R.
    Kidney Blood Press Res; 2009 Oct; 32(4):268-75. PubMed ID: 19776644
    [Abstract] [Full Text] [Related]

  • 6. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment.
    Penne EL, Neumann J, Klein IH, Oey PL, Bots ML, Blankestijn PJ.
    J Nephrol; 2009 Oct; 22(2):208-15. PubMed ID: 19384838
    [Abstract] [Full Text] [Related]

  • 7. Renal allograft protection with early angiotensin-converting enzyme inhibitors administration.
    Montanaro D, Gropuzzo M, Tulissi P, Boscutti G, Mioni R, Risaliti A, Baccarani U, Adani GL, Sainz M, Bresadola F, Mioni G.
    Transplant Proc; 2004 Apr; 36(3):692-4. PubMed ID: 15110633
    [Abstract] [Full Text] [Related]

  • 8. Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation.
    Kanno Y, Okada H, Yamaji Y, Nakazato Y, Suzuki H.
    QJM; 2005 Mar; 98(3):199-203. PubMed ID: 15728401
    [Abstract] [Full Text] [Related]

  • 9. Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factors.
    Jungers P, Hannedouche T, Itakura Y, Albouze G, Descamps-Latscha B, Man NK.
    Nephrol Dial Transplant; 1995 Mar; 10(8):1353-60. PubMed ID: 8538926
    [Abstract] [Full Text] [Related]

  • 10. Disease progression, response to ACEI/ATRA therapy and influence of ACE gene in IgA nephritis.
    Woo KT, Lau YK, Zhao Y, Liu FE, Tan HB, Tan EK, Stephanie FC, Chan CM, Wong KS.
    Cell Mol Immunol; 2007 Jun; 4(3):227-32. PubMed ID: 17601378
    [Abstract] [Full Text] [Related]

  • 11. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA, Onuigbo NT.
    QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
    [Abstract] [Full Text] [Related]

  • 12. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z, Amlodipine Versus Enalapril in Renal failure (AVER) Study Group.
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [Abstract] [Full Text] [Related]

  • 13. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
    Locatelli F, Carbarns IR, Maschio G, Mann JF, Ponticelli C, Ritz E, Alberti D, Motolese M, Janin G, Zucchelli P.
    Kidney Int Suppl; 1997 Dec; 63():S63-6. PubMed ID: 9407424
    [Abstract] [Full Text] [Related]

  • 14. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases.
    Seeman T, Dusek J, Vondrák K, Flögelová H, Geier P, Janda J.
    Am J Hypertens; 2004 May; 17(5 Pt 1):415-20. PubMed ID: 15110900
    [Abstract] [Full Text] [Related]

  • 15. Validation of some pathophysiological mechanisms of the CKD progression theory and outcome prediction in IgA nephropathy.
    Bazzi C, Rizza V, Casellato D, Stivali G, Rachele G, Napodano P, Olivieri G, Gallieni M, D'Amico G.
    J Nephrol; 2012 May; 25(5):810-8. PubMed ID: 22252844
    [Abstract] [Full Text] [Related]

  • 16. [Progression of chronic renal insufficiency and its prevention using angiotensin converting enzyme inhibitors and angiotensin antagonists].
    Tesar V.
    Vnitr Lek; 2003 May; 49(5):365-9. PubMed ID: 12908169
    [Abstract] [Full Text] [Related]

  • 17. [Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L?].
    Zhang GH, Hou FF, Zhang X, Liu QF.
    Zhonghua Nei Ke Za Zhi; 2005 Aug; 44(8):592-6. PubMed ID: 16194413
    [Abstract] [Full Text] [Related]

  • 18. Facility variation in utilization of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and chronic kidney disease.
    Tiwari A, Tseng CL, Kern EF, Maney M, Miller DR, Pogach L.
    Am J Manag Care; 2007 Feb; 13(2):73-9. PubMed ID: 17286527
    [Abstract] [Full Text] [Related]

  • 19. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency.
    Tong PC, Ko GT, Chan WB, Ma RC, So WY, Lo MK, Lee KF, Ozaki R, Chow CC, Cockram CS, Chan JC.
    Diabetes Obes Metab; 2006 May; 8(3):342-7. PubMed ID: 16634995
    [Abstract] [Full Text] [Related]

  • 20. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease.
    Dean BB, Dylan M, Gano A, Knight K, Ofman JJ, Levine BS.
    Curr Med Res Opin; 2005 Jul; 21(7):981-7. PubMed ID: 16004664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.